

Worldwide Health Sciences Fund (A)

A diversified global fund concentrating in health sciences companies.

A ▾
Share Class

ETHSX
Symbol

\$13.53 ▲\$0.02
NAV as of Apr 26, 2024



Fact Sheet
Mar 31, 2024

The Fund

The Fund invests worldwide in companies principally engaged in the discovery, development, production or distribution of products (or services) related to scientific advances in health care, including biotechnology, pharmaceuticals, diagnostics, managed health care, and medical equipment and supplies.

The Approach

The portfolio managers seek to purchase stocks that are reasonably priced in relation to their fundamental value and that the portfolio managers believe will grow in value over time regardless of short-term market fluctuations. The stock selection process is based on numerous factors, including the potential to increase market share (for larger companies), and the potential of research and development projects (for smaller companies). The team is based in Boston and London.

The Features


Growth in the health care sector is led by aging demographics, innovation and rising global incomes. As the global population ages and becomes wealthier, we believe health care spending is likely to continue to rise. Innovation drives growth in the sector, as increased scientific understanding leads to new breakthroughs.

Overview

Historical Returns (%)

as of Mar 31, 2024

03/31/2024



Fund at NAV	1.88	7.96	7.96	14.52	7.89	10.05	9.28
Fund w/Max Sales Charge	-3.49	2.32	2.32	8.51	5.98	8.87	8.69
MSCI World Health Care Index ¹	2.35	7.47	7.47	13.32	7.84	10.32	9.18

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.25%.

Fund Facts

as of Mar 31, 2024

Performance Inception	07/26/1985
Investment Objective	Long-term capital growth
Total Net Assets	\$1.0B
Expense Ratio (Gross) ²	1.18%
Expense Ratio (Net) ^{2,3}	1.14%
CUSIP	277902813

Top 10 Holdings (%)^{4,5}

as of Mar 31, 2024

Eli Lilly & Co	9.60
Novo Nordisk A/S	6.97
UnitedHealth Group Inc	6.82
AbbVie Inc	5.54
Thermo Fisher Scientific Inc	4.94
AstraZeneca PLC	4.55
Intuitive Surgical Inc	3.92
Danaher Corp	3.78
Boston Scientific Corp	3.56
Roche Holding AG	3.48
Total	53.16

Morningstar Rating™

as of Mar 31, 2024

Time Period	Rating	Funds in Health Category
Overall	★★★★★	159
3 Years	★★★★★	159
5 Years	★★★★★	136
10 Years	★★★	114

The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds and exchange-traded funds) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star.

The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Star ratings do not reflect the effect of any applicable sales load. Hollow stars denote Morningstar Extended Performance Ratings and are considered estimates based on the performance of the fund's oldest share class, adjusted for fees and expenses.

©2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Portfolio Management

[Jason Kritzer, CFA](#)

[Managed Fund since 2016](#)

[Samantha Pandolfi, CFA](#)

[Managed Fund since 2016](#)

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS


The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, more established companies. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund's performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the [Fund prospectus](#) for a complete description.

- 1. MSCI World Health Care Index is an unmanaged index of health care sector equities within the MSCI World Index. Unless otherwise stated, index returns do not reflect the effect of any applicable sales charges, commissions, expenses, taxes or leverage, as applicable. It is not possible to invest directly in an index. Historical performance of the index illustrates market trends and does not represent the past or future performance of the fund. MSCI indexes are net of foreign withholding taxes. Source: MSCI. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.
- 2. Source: Fund prospectus.
- 3. Net expense ratio reflects a contractual expense reimbursement that continues through 12/31/24. Without the reimbursement, if applicable, performance would have been lower.
- 4. Top 10 Holdings excludes cash and equivalents.
- 5. Percent of total net assets.

Performance

Historical Returns (%)

as of Mar 31, 2024



Fund at NAV	1.88	7.96	7.96	14.52	7.89	10.05	9.28
Fund w/Max Sales Charge	-3.49	2.32	2.32	8.51	5.98	8.87	8.69
MSCI World Health Care Index ¹	2.35	7.47	7.47	13.32	7.84	10.32	9.18
Morningstar Health Category ⁶	1.19	6.33	6.33	11.04	-0.38	7.51	9.04

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund's current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative. Max Sales Charge: 5.25%.

Calendar Year Returns (%)

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Fund at NAV	27.39	8.39	-14.89	16.24	5.98	25.99	13.03	22.06	-9.43	5.66
MSCI World Health Care Index ¹	18.10	6.60	-6.81	19.80	2.51	23.24	13.52	19.80	-5.41	3.76

Fund Facts

Performance Inception	07/26/1985
Expense Ratio (Gross) ²	1.18%
Expense Ratio (Net) ^{2,3}	1.14%
Distribution Frequency	Annually

Risk Measures (3 Year)⁷

as of Mar 31, 2024	
Alpha (%)	-0.37
Beta	1.07
R-Squared (%)	96.94
Standard Deviation (%)	15.40
Sharpe Ratio	0.35

Morningstar Rating™

as of Mar 31, 2024

Time Period	Rating	Funds in Health Category
Overall	★★★★★	159
3 Years	★★★★★	159
5 Years	★★★★★	136
10 Years	★★★	114

The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds and exchange-traded funds) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star.

The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Star ratings do not reflect the effect of any applicable sales load. Hollow stars denote Morningstar Extended Performance Ratings and are considered estimates based on the performance of the fund's oldest share class, adjusted for fees and expenses.

©2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

NAV History

Date	NAV	NAV Change
Apr 26, 2024	\$13.53	\$0.02
Apr 25, 2024	\$13.51	-\$0.02
Apr 24, 2024	\$13.53	-\$0.06
Apr 23, 2024	\$13.59	\$0.25
Apr 22, 2024	\$13.34	\$0.10
Apr 19, 2024	\$13.24	-\$0.01

Date	NAV	NAV Change
Apr 18, 2024	\$13.25	-\$0.05
Apr 17, 2024	\$13.30	-\$0.01
Apr 16, 2024	\$13.31	\$0.00
Apr 15, 2024	\$13.31	-\$0.05

Distribution History⁸

Ex-Date	Distribution	Reinvest NAV
Dec 07, 2023	\$0.01660	\$12.51
Dec 08, 2022	\$0.02720	\$12.94
Dec 09, 2021	\$0.03450	\$13.86

No records in this table indicates that there has not been a distribution greater than .0001 within the past 3 years.

[Fund prospectus](#)

Capital Gain History⁸

Ex-Date	Short-Term	Long-Term	Reinvest NAV
Dec 07, 2023		\$0.30770	\$12.51
Dec 08, 2022		\$0.53510	\$12.94
Dec 09, 2021	\$0.23260	\$0.93850	\$13.86

No records in this table indicates that there has not been a capital gain greater than .0001 within the past 3 years.

[Fund prospectus](#)

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, more established companies. The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund's performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the [Fund prospectus](#) for a complete description.

1. MSCI World Health Care Index is an unmanaged index of health care sector equities within the MSCI World Index. Unless otherwise stated, index returns do not reflect the effect of any applicable sales charges, commissions, expenses, taxes or leverage, as applicable. It is not possible to invest directly in an index. Historical performance of the index illustrates market trends and does not represent the past or future performance of the fund. MSCI indexes are net of foreign withholding taxes. Source: MSCI. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

2. Source: Fund prospectus.

3. Net expense ratio reflects a contractual expense reimbursement that continues through 12/31/24. Without the reimbursement, if applicable, performance would have been lower.

6. The Morningstar Health Category includes funds that invest in companies in the medical and health-care industries.

7. Alpha measures risk-adjusted performance, showing excess return delivered at the same risk level as the benchmark. Beta measures the volatility


of a fund relative to the overall market. R-Squared represents the percentage of the portfolio's movement that can be explained by the general movement of the market. Standard deviation measures the historic volatility of a fund. Sharpe Ratio uses standard deviation and excess return to determine reward per unit of risk.

8. A portion of the Fund's returns may be comprised of return of capital or short term capital gains. The Fund will determine the tax characteristics of all Fund distributions after the end of the calendar year and will provide shareholders such information at that time. Please consult your tax advisor for further information.

Portfolio

Asset Mix (%)^{5,9}

as of Mar 31, 2024



Portfolio Statistics

as of Mar 31, 2024

Number of Holdings	42
Active Share ¹⁰	43.10%

Sector Breakdown (%)⁵

as of Mar 31, 2024

Sector	Fund	MSCI World Health Care Index ¹
Health Care Distributors	2.94	2.03
Health Care Equipment	14.32	16.11
Health Care Facilities	2.07	1.09
Health Care Services	0.00	3.57
Health Care Supplies	5.99	2.78
Health Care Technology	0.19	0.53
Life Sciences Tools & Services	11.74	9.58
Managed Health Care	8.06	8.83
Pharma	41.27	41.75
Other	0.62	0.05
Cash	0.00	0.00

Assets by Country (%)⁵

as of Mar 31, 2024


United States	75.94
Denmark	6.97
United Kingdom	4.55
Switzerland	4.08
France	3.23
Australia	2.08
Italy	0.86
Germany	0.83
Netherlands	0.83
Japan	0.63
Total	100.00

[View All](#)

Geographic Mix (%)⁵

as of Mar 31, 2024

03/31/2024



North America	75.94
Europe	21.35
Asia/Pacific	2.70
Cash & Other Assets	0.00
Total	100.00

Fund Holdings (%)^{5,11}

as of Feb 29, 2024

Holding	% of Net Assets
Eli Lilly & Co	9.40%
UnitedHealth Group Inc	6.88%
Novo Nordisk A/S	6.56%
AbbVie Inc	5.41%
Thermo Fisher Scientific Inc	5.11%
AstraZeneca PLC	4.31%
Danaher Corp	3.96%
Intuitive Surgical Inc	3.83%
Roche Holding AG	3.61%
Johnson & Johnson	3.54%
View All	

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.

RISK CONSIDERATIONS

The value of investments held by the Fund may increase or decrease in response to economic, and financial events (whether real, expected or perceived) in the U.S. and global markets. The value of equity securities is sensitive to stock market volatility. Because the Fund investments may be concentrated in a particular industry, the Fund share value may fluctuate more than that of a less concentrated fund. Investments in foreign instruments or currencies can involve greater risk and volatility than U.S. investments because of adverse market, economic, political, regulatory, geopolitical, currency exchange rates or other conditions. Smaller companies are generally subject to greater price fluctuations, limited liquidity, higher transaction costs and higher investment risk than larger, more established companies.

The Fund is exposed to liquidity risk when trading volume, lack of a market maker or trading partner, large position size, market conditions, or legal restrictions impair its ability to sell particular investments or to sell them at advantageous market prices. The impact of the coronavirus on global markets could last for an extended period and could adversely affect the Fund's performance. No fund is a complete investment program and you may lose money investing in a fund. The Fund may engage in other investment practices that may involve additional risks and you should review the [Fund prospectus](#) for a complete description.

1. MSCI World Health Care Index is an unmanaged index of health care sector equities within the MSCI World Index. Unless otherwise stated, index returns do not reflect the effect of any applicable sales charges, commissions, expenses, taxes or leverage, as applicable. It is not possible to invest directly in an index. Historical performance of the index illustrates market trends and does not represent the past or future performance of the fund. MSCI indexes are net of foreign withholding taxes. Source: MSCI. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

5. Percent of total net assets.

9. A delay in transaction settlement may result in a negative cash position.

10. Active Share is a measure of the differentiation of the holdings of a portfolio from the holdings of its appropriate benchmark index. It is calculated as one half of the sum of the absolute value of the differences found between the portfolio weights and the benchmark weights.

11. The following list reflects unaudited securities holdings (excluding derivatives positions). Holdings information may differ if presented as of trade date. Due to rounding, holdings of less than 0.005% may show as 0.00%. Portfolio information subject to change due to active management.

Management



Jason Kritzer, CFA

Managing Director, Portfolio Manager,
Analyst
Joined Eaton Vance 2012

Biography

Jason is a managing director of Morgan Stanley. He is a portfolio manager and an analyst on the Eaton Vance Value team. As a portfolio manager, he is responsible for buy and sell decisions, portfolio construction and risk management for health care portfolios. As an analyst, he is responsible for coverage of the pharmaceutical and biotechnology industries. He joined Eaton Vance in 2012. Morgan Stanley acquired Eaton Vance in March 2021.

Jason began his career in the investment management industry in 1999. He was previously affiliated with BlackRock, Inc. as a director and equity analyst covering the health care sector, and Putnam Investments as an equity research analyst covering health care, technology and business services. Prior to the investment management industry, Jason worked in the computer industry for Digital Equipment Corporation.

Jason earned a B.S.B.A. from Boston University, School of Management and an MBA from Columbia University, School of Business. He is a member of the Columbia Business School Ambassador Program. He is a CFA charterholder.

Education

- B.S.B.A. Boston University
- M.B.A. Columbia University

Experience

- Managed Fund since 2016



Samantha Pandolfi, CFA

Managing Director, Portfolio Manager,
Analyst
Joined Eaton Vance 2015

Biography

Samantha is a managing director of Morgan Stanley. She is a portfolio manager and an analyst on the Eaton Vance Global Equity team. As a portfolio manager, she is responsible for buy and sell decisions, portfolio construction and risk management for health care portfolios. She is primarily responsible for covering the health care sector for global large-cap and small-cap portfolios. She joined Eaton Vance in 2015. Morgan Stanley acquired Eaton Vance in March 2021.

Samantha began her career in the investment management industry in 2000. Before joining Eaton Vance, she was an executive director and European and global health care portfolio manager at Goldman Sachs Asset Management (GSAM) for 15 years. She has also covered apparel/luxury goods, support services, leisure and cosmetics.

Samantha earned a J.D. from Università degli Studi La Sapienza and an MBA from INSEAD. She is a CFA charterholder.

Education

- M.B.A. INSEAD
- J.D. Università degli Studi La Sapienza

Experience

- Managed Fund since 2016

Literature



Fact Sheet

[Download](#) - Last updated: Mar 31, 2024



Annual Report

[Download](#) - Last updated: Aug 31, 2023



Full Prospectus

[Download](#) - Last updated: Jan 1, 2024



Q1 Holdings

[Download](#) - Last updated: Nov 30, 2023



Q3 Holdings

[Download](#) - Last updated: May 31, 2023



Holdings - Form N-PORT

[Download](#)



SAI

[Download](#) - Last updated: Jan 1, 2024



Semi-Annual Report

[Download](#) - Last updated: Feb 28, 2024



Summary Prospectus

[Download](#) - Last updated: Jan 1, 2024



HEADQUARTERS

One Post Office Square
Boston, MA 02110

Investments

[Eaton Vance Funds](#)

[Parametric Funds](#)

[Calvert Funds](#)

[Separately Managed Accounts](#)

[Closed-End Funds and Term Trusts](#)

Insights

[Advisory Blog](#)

[The BEAT](#)

[Market Update Events](#)

[The Advisor Institute](#)

Taxes & Tools

[Investment Tax Center](#)

[Tax Information](#)

[Investment Tax Calculator](#)

[Laddered Investing Interest Rate
Scenario Tool](#)

[Concentrated Stock Position
Calculator](#)

[Tax-Equivalent Yield Calculator](#)

Resources

[Forms & E-Delivery](#)

[Mutual Funds & Abandoned
Property](#)

[DST Vision](#)

[Active Advisor](#)

[Corporate Filings](#)

[Annual Reports](#)

[Press Releases](#)

[Diversity and Inclusion](#)

To report a website vulnerability, please go to [Responsible Disclosure](#).

Eaton Vance is part of Morgan Stanley Investment Management, the asset management division of Morgan Stanley.

For USA PATRIOT Act Disclosure Notice please click [here](#).

 This image indicates content designed specifically for Financial Advisors / Investment Professionals. This material is not to be used with the public.

Before investing in any Eaton Vance, Calvert or Morgan Stanley Investment Management Inc.-advised fund, prospective investors should consider carefully the investment objective(s), risks, and charges and expenses. Read the prospectus carefully before you invest or send money. For **open-end mutual funds**, the current prospectus contains this and other information. To obtain an **open-end mutual fund** prospectus or summary prospectus and the most recent annual and semiannual shareholder reports, contact your financial advisor or [download a copy here](#). For **closed-end funds**, you should contact your financial advisor. To obtain the most recent annual and semi-annual shareholder report for a closed-end fund contact your financial advisor or [download a copy here](#). To obtain an **exchange-traded fund**, ("ETF") prospectus or summary prospectus, contact your financial advisor or [download a copy here](#).

Before purchasing any **variable product**, consider the objectives, risks, charges, and expenses associated with the underlying investment option(s) and those of the product itself. For a prospectus containing this and other information, contact your investment or insurance professional. Read the prospectus carefully before investing.

NOT FDIC INSURED | OFFER NO BANK GUARANTEE | MAY LOSE VALUE | NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY | NOT A DEPOSIT

Eaton Vance does not provide tax or legal advice. Prospective investors should consult with a tax or legal advisor before making any investment decision. The information on this Web page is for U.S. residents only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities in any jurisdiction to any person to whom it is not lawful to make such an offer.

© Eaton Vance Management. All rights reserved.

Eaton Vance open-end mutual funds are offered through Eaton Vance Distributors, Inc. One Post Office Square, Boston, MA 02110. Member [FINRA](#) / [SIPC](#). Exchange-traded funds are distributed by Foreside Fund Services, LLC.

Publication details: Monday, April 29, 2024 9:49 AM

Page ID: ETHSX - <https://www.eatonvance.com/worldwide-health-sciences-fund-ethsx.php>